Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dalgarno

Showing results (471-480 of 479) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 479 results.
Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agentsChi B Vu, George P Luke, Noriyuki Kawahata, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Nature Communications|July 24, 2024
Pannexin-1 channel inhibition alleviates opioid withdrawal in rodents by modulating locus coeruleus to spinal cord circuitryCharlie H T Kwok, Erika K Harding, Nicole E Burma, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Journal of Medicinal Chemistry|May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma KinaseWei-Sheng Huang, Shuangying Liu, Dong Zou, et al.
Journal of Medicinal Chemistry|June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2022
Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancerWei-Sheng Huang, Feng Li, Yongjin Gong, et al.
Cancers|July 2, 2021
Dissection of <i>PIK3CA</i> Aberration for Cervical Adenocarcinoma OutcomesTony K H Chung, Graeme Doran, Tak-Hong Cheung, et al.
Pageof 48

Showing results (471-480 of 479) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 479 results.
Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agentsChi B Vu, George P Luke, Noriyuki Kawahata, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Nature Communications|July 24, 2024
Pannexin-1 channel inhibition alleviates opioid withdrawal in rodents by modulating locus coeruleus to spinal cord circuitryCharlie H T Kwok, Erika K Harding, Nicole E Burma, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Journal of Medicinal Chemistry|May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma KinaseWei-Sheng Huang, Shuangying Liu, Dong Zou, et al.
Journal of Medicinal Chemistry|June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2022
Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancerWei-Sheng Huang, Feng Li, Yongjin Gong, et al.
Cancers|July 2, 2021
Dissection of <i>PIK3CA</i> Aberration for Cervical Adenocarcinoma OutcomesTony K H Chung, Graeme Doran, Tak-Hong Cheung, et al.
Pageof 48